Vital Signs - 22 May 2006


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on May 22, 2006, provides a strategic overview of the trickle down effects of budget cuts on biomedical research, potentially hampering the pipeline of innovation. Additionally, an emerging company profile is provided on High Throughput Genomics, Inc, a company dedicated to the development of next generation technology for the quantitative measurement of gene expression, DNA and proteins. Reimbursement and regulatory news from the FDA and CMS are also provided for the week of May 10 - May 16, 2006.

Table of Contents

Vital Signs - 22 May 2006A Constrained Pipeline to Innovation: The Trickle-Down Effects of Budget Cuts to Public Biomedical ResearchA Constrained Pipeline to Innovation: The Trickle-Down Effect of Budget Cuts to Public Biomedical Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.